Article
Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.
All News
Article
Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.
Article
Arthritis & Rheumatology has published the results of a subanalysis from tocilizumab (TCZ) clinical trials showing that Il-6 inhibition was associated with preservation of lung function patients with early systemic sclerosis (SSc).
Article
Metanalysis of patients with diffuse alveolar hemorrhage (DAH), show this to be a rare and life-threatening complication of systemic lupus erythematosus (SLE), that is more apt to affect older, severe lupus patients with active infection.
Article
Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.
Article
There is a preponderance and mounting evidence that hydroxychloroquine is ineffective in COVID-19 infection; and now the NEJM reports a the results of a trial where HCQ given as post-COVID exposure therapy failed to prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons.
Article
For a variety of reasons, the use of anti-malarials (chloroquine and hydroxychloroquine) rose dramatically in the pandemic; notable was the lack of proven benefit and the dramatic risk in reported adverse drug reactions (ADRs) associated with these drugs being used to treat SARS-CoV-2.
Article
Analysis of the NHANES (National Health and Nutrition Examination Survey) data suggests that one-third of the risk of developing rheumatoid arthritis (RA) in the USA is attributable smoking, obesity and alcohol intake.
Article
Dr. Jack Cush reviews this past week's journal articles and news features on RheumNow.com. Colchicine, vaccine rollout, risk of RA in endometriosis patients, tREACH trial, lupus nephritis news, rheumatology burnout and more.
Article
Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.
Article
A press release from Montreal Heart Institute announced that the COLCORONA clinical trial provided evidence of the protective effect of colchicine; demonstrating a 21% reduced risk of death or hospitalizations in patients with COVID-19 compared to placebo. COLCORONA trial was a contact-less, randomized, double-blind, placebo-controlled study of 4,488 non-hospitalized patients from Canada, the U.S., Europe, South America and South Africa.
Dr. John Cush
Tweet
News Feature: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease
https://t.co/6A4muejeH9 https://t.co/xQbIoEEscv
Dr. John Cush
Tweet
Today the FDA approved tocilizumab (Actemra) for use in Systemic Sclerosis-Associated Interstitial Lung Disease for "Slowing the rate of decline in pulmonary function in adult patients with SSc-ILD" Rec dose is 162 mg SC q week (IV dose not approved) https://t.co/HXTRPiYEfZ
Dr. John Cush
Tweet
While RA incurrs a 2 fold risk of CHF; the use of HCQ does not add to a CHF risk. Mayo nested case-control study, compared RA w/ CHF vs nonCHF RA pts, showing HCQ use, nor duration of use, failed to increase CHF (OR: 0.96).https://t.co/Tx9jr07C7i
Dr. John Cush
Tweet
We are excited to announce that Jeff Sparks ( @jeffsparks) will be leading a discussion on ILD in RA at RheumNow Live this March.
Register to attend today.
https://t.co/uwxOVh142F https://t.co/bnittqkhKQ
Dr. John Cush
Tweet
Lung Preservation w/ Tocilizumab in Early Systemic Sclerosis
Arthritis & Rheumatology has published the results of a subanalysis from TCZ clinical trials showing that Il-6 inhibition is related with preservation of lung function patients with early SSc.
https://t.co/2BwWQWEkri https://t.co/pjVc8YTDwU
Dr. John Cush
Tweet
CTD associated pulmonary HTN has improved sincd 2010. Metanalysis of 11 RCTs (4,329 pts) & 19 registries (9,739 pts); 5 RCTs find PAH Rx assoc w/ 36% lower mortality/morbidity. Registry data shows better PAH survival since 2010 (73% vs 65% @3yrs) https://t.co/0BkO70AQfi
Dr. John Cush
Tweet
Analysis of incident #RA in UK Clinical Practice registry shows recent prednisone >=7.5mg/d is assoc w/ hypertension in RA. In 17760 RA pts, 42% were Rx steroids; recent GC yielded a 17% increase in HTN (HR 1.17); only >7.5mg/D implicated https://t.co/qUKs2oZZUV https://t.co/pWmD4nKs6U
Dr. Rachel Tate
Tweet
Dr. Shenoi Suspect autoinflammatory Dz: patterned fevers MSK and skin involvement Serositis Other - aphthous ulcers, CNS (stroke, basal ganglia calcification,) ILD, LN, lipodystrophy) ethnicity (FMF or Mediterranean) Family Hx -- Testing options! #RWCS2021 @RheumNow @RWCSmtg https://t.co/DZk4hsxbk4
Dr. John Cush
Tweet
Systemic Sclerosis Rapid Onset Pulmonary Arterial Hypertension Pulmonary Capillary Hemangiomatosis
RWCS 2021 Poster Session by Dr. Jason Melehani, Stanford University
https://t.co/wfxiY2VqcN
